+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antimicrobial Susceptibility of Klebsiella pneumoniae Producing Extended-Spectrum beta-lactamase (ESBL) Isolated in Hospitals in Brazil



Antimicrobial Susceptibility of Klebsiella pneumoniae Producing Extended-Spectrum beta-lactamase (ESBL) Isolated in Hospitals in Brazil



Brazilian Journal of Infectious Diseases 1(4): 196-203



The prevalence of klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) has been increasing all over the world. Infections caused by ESBL producing isolates are difficult to detect with current susceptibility tests, and are difficult to treat. ESBLs confer resistance to all currently available beta-lactam, except carbapenems. In addition, ESBL production is usually associated with resistance to other classes of antimicrobial agents such as aminoglycosides and quinolones. The objective of this study was to evaluate the in vitro susceptibility patterns of ESBL producing K pneumoniae isolated in Brazil. Seventy-two strains were tested using E test against 30 antimicrobial agents, including carbapenems, second and third generation cephalosporins, aminoglycosides, quinolones, and some new compounds. The most active compounds (i.e. 100% susceptibility) were meropenem (MIC90, 0.125µg/mL), imipenem (MIC90, 0.25µg/mL), and cefotetan (MIC90, 2µg/mL). Ciprofloxacin (MIC90, 1µg/mL, 94% susceptibility) and cefepime (MIC90, 6µg/mL, 92% susceptibility), were also very active against our collection of ESBL producing K pneumoniae. None of the six aminoglycosides showed good activity against these strains (16% to 41% susceptibility) and only 39% of the isolates were susceptible to piperacillin/tazobactam. The results of our study indicated that the carbapenems are the most active compounds against ESBL producing L pneumoniae in Brazil, and ciprofloxacin remains very active against these strains. Cefotetan and cefepime were also very active against ESBL producing K.pneumoniaein Brazil; however, further studies are necessary to evaluate the role of these cephalosporins in the treatment of infections due to ESBL producing strains.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045277322

Download citation: RISBibTeXText

PMID: 11105137


Related references

Prevalence, antimicrobial susceptibility and molecular typing of extended-spectrum beta-lactamase producing Klebsiella pneumoniae from Brazil. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 85, 1997

Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in Portugal. International Journal of Antimicrobial Agents 34(1): 29-37, 2009

Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae. PhytoTherapy Research 19(7): 612-617, 2005

Extended-spectrum β-lactamases producing Klebsiella pneumoniae isolated in two hospitals in Goiânia/Brazil: detection, prevalence, antimicrobial susceptibility and molecular typing. Brazilian Journal of Microbiology 39(4): 608-612, 2008

Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Journal of Clinical Microbiology 42(1): 269-275, 2004

In vitro-susceptibility of Brazilian extended-spectrum beta-lactamase producing Klebsiella pneumoniae to 20 antimicrobial agents. Abstracts of the General Meeting of the American Society for Microbiology 97: 16, 1997

Epidemiology and antimicrobial susceptibility profiles of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichiacoli in China. Brazilian Journal of Microbiology 50(3): 669-675, 2019

Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Annals of Saudi Medicine 25(3): 239-242, 2005

Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes. Infection Control and Hospital Epidemiology 29(11): 1026-1034, 2008

Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics. Medical Science Monitor 8(3): Br100, 2002

Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital. Journal of Research in Pharmacy Practice 4(3): 153-159, 2015

Extended-spectrum beta-lactamase (ESBL) CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae in Sofia, Bulgaria. Clinical Microbiology and Infection 10(8): 752-755, 2004

Antimicrobial susceptibility pattern and prevalence of extended spectrum beta-lactamase (ESBLs) producing strains of Klebsiella pneumoniae from a major hospital in New Delhi. Journal of Communicable Diseases 36(1): 17-26, 2004

Sulfonamide Resistance Genes (sul) M in Extended Spectrum Beta Lactamase (ESBL) and Non-ESBL Producing Escherichia coli Isolated From Iranian Hospitals. Jundishapur Journal of Microbiology 8(7): E19961, 2015

Extended spectrum beta lactamase (ESBL) producing Escherichia coli and klebsiella pneumoniae in diabetic foot infection. Indian Journal of Medical Microbiology 26(3): 281-282, 2008